SHOP APOTHEKE EUROPE N.V.
EXTRAORDINARY GENERAL MEETING

VENLO, 6 November 2017
Disclaimer

Important Information

This Presentation and information included therein has been prepared solely by Shop Apotheke Europe N.V. (the "Company"). It is not a securities prospectus and does not contain all information with regard to the Company and/or its securities that may be essential to make an investment decision with respect to the Company's securities. An investment decision must be based solely on any related securities prospectus that will be made available on the Company’s website. Such prospectus will also include a description of the risks specific to the situation of the Company and/or the offered securities which are material for the taking of any investment decisions. This Presentation merely makes general statements with regard to certain investment risks, which, in the Company’s assessment, are of particular importance with respect to the Company.

For the purposes of this notice, the “Presentation” includes this document, its contents or any part of it and any related video or oral presentation, any question and answer session and material discussed during the presentation meeting. No written material, including any copies of this Presentation, will be distributed during or following the presentation meeting.

Additional Important Information

This Presentation has not been verified independently and is provided for information purposes only, and should not be generally distributed directly or indirectly into or within the United States, Canada, Australia, Japan or the United Kingdom, or in any other jurisdiction where such distribution would be unlawful. It does not constitute or form part of, and should not be construed as an offer or invitation or recommendation to, purchase or sell or subscribe for, or as any solicitation of any offer to purchase or subscribe for, any securities of the Company, in any jurisdiction. Neither this Presentation, nor any part thereof nor anything contained or referred to therein, nor the fact of its distribution, should form the basis of or be relied on in connection with, or serve as an inducement in relation to, a decision to purchase or subscribe for or enter into any contract or make any other commitment whatsoever in relation to any such securities. The risk included in any prospectus must be considered carefully before taking any investment decision. It should be noted that a final decision as to whether, when and the terms on which any offer of securities may or may not take place has not been taken by the Company.

This Presentation may contain “forward-looking” information which may include, but is not limited to, projections, forecasts or estimates of cash flows, yields or return, scenario analyses and model illustrations. Any forward-looking information is based upon certain assumptions about future events or conditions and is intended only to illustrate hypothetical results under those assumptions (not all of which are specified herein or can be ascertained at this time).

Unless otherwise stated, the Company is the source of the information contained herein. The Company and its advisers, including Citigroup Global Markets Deutschland AG and Lilja & Co. GmbH (together, the Financial Advisers) and any of their respective affiliates, personally liable partners, directors, officers, employees, advisers or agents, shall accept no responsibility and have no liability to you or to any third parties, for the quality, accuracy, fairness, timeliness, continued availability or completeness of any data or calculations contained and/or referred to in this Presentation (or whether any information has been omitted from the Presentation) or any other information relating to the Company, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available nor for any special, direct, indirect, incidental or consequential loss or damage which may be sustained because of the use of the information contained and/or referred to in this Presentation or otherwise arising in connection with the information contained and/or referred to in this Presentation, provided that this exclusion of liability shall not exclude or limit any liability under any law or regulation applicable to the Company or the Financial Advisers that may not be excluded or restricted.

All information in this Presentation is current at the time of publication but may be subject to change in the future. The Company and the Financial Advisers disclaim any obligation to update or revise any statements, in particular forward-looking statements, to reflect future events or developments. This Presentation is not an offer of securities for sale in the United States of America. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Any public offering of securities to be made in the United States of America would be made by means of a prospectus that could be obtained from the issuer and that would contain detailed information about the company and management, as well as financial statements. There will be no public offer of the securities in the United States of America. Any decision to purchase any product or enter into any transaction referred to in this Presentation should be based upon the information contained in any associated offering document. This Presentation is not intended for distribution to, or to be used by, any person or entity in any jurisdiction or country which distribution or use would be contrary to law or regulation.
Disclaimer (cont’d)

In receiving or otherwise accessing this Presentation, you will be deemed to have represented, agreed and undertaken (i) that you are permitted, in accordance with all applicable laws, to receive such information, (ii) that you are solely responsible for your own assessment of the business and financial position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company and (iii) that you have read and agree to comply with the contents of this notice, including, without limitation, the obligation to keep the Presentation and its contents confidential.

This Presentation has been presented to you solely for your information and must not be copied, reproduced, distributed or passed (in whole or in part) to any other person at any time. The distribution of the Presentation in certain jurisdictions may be restricted and accordingly it is the responsibility of any person into whose possession the Presentation falls to inform themselves about and observe any restrictions. The Presentation is only addressed to and directed at persons: (i) in member states of the European Economic Area ("EEA") who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive [Directive 2003/71/EC and amendments thereto, including Directive 2010/73/EU, to the extent implemented in the relevant member state of the EEA] ("Qualified Investors"); (ii) in the United Kingdom, at Qualified Investors who are persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or who are high net worth companies, unincorporated associations and other bodies who fall within article 49(2)(a) to (d) of the Order; or (iii) persons to whom it may otherwise be lawful to communicate it to (all such persons together being referred to as “Relevant Persons”). The Presentation is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons.

You should not treat the contents of this Presentation as advice relating to legal, taxation or investment matters, and must make their own assessments concerning such matters and other consequences of a potential investment in the Company and its securities, including the merits of investing and related risks.
AGENDA

1. Opening

2. Agenda item 2 (proposal 1): Approval of the Transaction (within the meaning of Section 2:107a of the Dutch Civil Code) (voting item).

3. Agenda item 3 (proposal 2): Issuance of new ordinary shares in the share capital of the Company in connection with the Transaction (voting item).

4. Agenda item 4.a. (proposal 3.a.): Designation of the managing board of the Company as the corporate body authorised to issue shares and/or grant rights to acquire shares subject to certain conditions (voting item);

5. Agenda item 4.b. (proposal 3.b.): Designation of the managing board of the Company as the corporate body authorised to restrict or exclude the pre-emptive rights upon the issue of shares and/or the granting of rights to acquire shares as described in agenda item 4.a. (proposal 3.a.) subject to certain conditions (voting item).

6. Agenda item 5: Questions, answers and any other business

7. Collection of voting slips

8. Closing
1. Opening
2. Agenda item 2 (proposal 1): Approval of the Transaction (within the meaning of Section 2:107a of the Dutch Civil Code)
Transaction background, strategic rationale and details
Rationale: Creating Europe’s Largest Online Pharmacy

- Combining the OTC and Rx offering
- Serving the whole family
- Creating leadership position in Europe
Rx is a Large and Attractive Market, Perfectly Suited for E-commerce...

Large Opportunity Complimentary to OTC / BPC(1)
2017 Continental European Total Addressable Market ("TAM"), €bn (excl. VAT)

Well Suited for E-commerce(2)

With Highly Attractive Online Penetration Potential(3)
2017E, Online Penetration in Germany

Source: (1) Sempora, OTC is defined as non-prescription medication. Continental Europe excludes the UK and certain small EU countries; countries included are: Germany, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Portugal, Czech Republic, Hungary, Sweden, Bulgaria, Denmark, Slovakia, Norway, Austria. SAE is OTC and Pharma Related BPC. (2) Please refer to page 11. (3) Sempora and Euromonitor. All market sizes exclude VAT.
In October 2016, a key regulatory ruling impacted our...

“In October 2016 the Court of Justice for the European Union (CJEU) ruled that national legislation in Germany that fixes prices of prescription, only medicines interferes with free trade within the European Union.”

Source: (1) EHS Company information.
Rx in Continental Europe Presents a TAM 4x Larger Than OTC & BPC...

Rx Presents a Huge Addressable Market\(^{(1)}\)...
2017, Continental Europe, €bn (excl. VAT)

- **Rx**: €129bn
- **OTC**: €15bn
- **Pharma Related BPC**: €20bn

...and German Rx Alone Doubles Our TAM Today\(^{(1)}\)
2017, €bn (excl. VAT)

- **Continental Europe OTC & Pharma Related BPC**: €35bn
- **Germany Rx**: €36bn

Rx growth is supported by long term growth in overall healthcare spending

Source: (1) Sempora. All market sizes exclude VAT. Market size for Continental Europe, excludes the UK and certain small EU countries; countries included are: Germany, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Portugal, Czech Republic, Hungary, Sweden, Bulgaria, Denmark, Slovakia, Norway, Austria. Note: OTC is defined as non-prescription medication.
E-prescriptions

- Currently available in

- Reduced healthcare costs

- Increased security

Liberalization of Rx Regulation

- E-commerce prescription drugs availability

<table>
<thead>
<tr>
<th>Country Permitted?</th>
<th>Country Permitted?</th>
</tr>
</thead>
<tbody>
<tr>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>✓</td>
<td>✗</td>
</tr>
<tr>
<td>✓</td>
<td>✗</td>
</tr>
</tbody>
</table>

*E-prescription available but E-commerce/mail-order Rx not permitted

- Governments could consider liberalizing E-commerce for prescription drugs, enabling access to a large addressable market

Source: (1) James Dudley, selected countries shown, which are relevant for SAE, PWC and McKinsey. (2) Eurostat.
Shop Apotheke Europe N.V. Proposes to Acquire Europa Apotheek to Capitalize on this Opportunity...

1. **Established and Trusted Player in an Attractive Market**
   - c.80% of revenue from Rx products\(^{(1)}\)
   - c.25% Rx mailorder market share for 2017
   - Over 1mn parcels per year
   - Trusted partner since 2001

2. **Highly Attractive Customer Profile**
   - Focused on chronically ill patients with low churn rate
   - c.90% Repeat Orders / c.0.7% Returns
   - Total average cart size\(^{(2)}\) of c. €187
   - Cart size: c.€300 Rx\(^{(3)}\) vs. c.€60 OTC\(^{(4)}\)

3. **Excellent Value Proposition**
   - Smart: 7 patient-care programs
   - Attractive RX bonus model

4. **Experienced Management Team**
   - Founder-led and long-term commitment
   - Long-Term Sector Experience

Source: Company information.
Note: \(^{(1)}\) Based on 1H 2017. \(^{(2)}\) Total gross revenue (incl. vat) / number of orders as per H1 2017. \(^{(3)}\) Average cart size of orders containing Rx products. \(^{(4)}\) Average cart size of pure OTC orders.
...and Create the Leading Pan European Online Pharmacy

1. SAE is well placed to capitalize on the B2C Rx E-commerce opportunity
   - Google Trend Awareness
     - YTD 2017
     - Across time...
     - ...and across Germany

2. Create a comprehensive offering for the entire family
   - With meaningful synergies
   - And smooth integration

3. With meaningful synergies
   - Cost
     - Common brand
     - c. €2.0-2.5mn of annual run rate cost synergies
   - Revenue
     - Larger Basket Size
     - Higher Order Frequency
     - Cross-selling OTC to Rx Customers

4. And a smooth integration
   - Common Logistics & Technology Platform

Source: (1) Google Trends. (2) SAE and EHS company information.
SAE is Well Placed to Capitalize on the B2C Rx E-commerce Opportunity

Online Marketing Strategy
- Online Marketing Experts
- Google
- Facebook
- YouTube

Online Presence
- Strong Online Brand
- Interest Over Time, 2017YTD
- SAE-dominated region
- DM-dominated region

User Base
- Large and Growing Rapidly
- Active Users, in mn

Source: (1) Kaske. (2) Google Trends. (3) Company filings.
SAE + EHS: Comprehensive Offering for the Entire Family

Combined Entity’s Customer Age Profile\(^{(1)}\)
\% of Total Active Customer

SAE’s Customer Age Profile
- Targets relatively younger population (OTC / BPC shoppers)
- <30\% of active customers above 65 years old
- 63\% of active customers between 30-65 years old

EHS’s Customer Age Profile
- Targets relatively older population (Rx consumers)
- 50\%+ of active customers above 65 years old
- 45\% of active customers between 30-65 years old

Source: SAE company information, EHS company information. (1) Excludes age range 0-17
Substantial Revenue and Cost Synergies

Revenue\(^{(1)}\)...

1. Larger Basket Size

2. Highly Effective Rx-OTC Cross-Selling

- Comes for Rx
- Leaves with Rx+OTC basket

Customer Lifetime Value
2014 Cohort, €

- Rx & OTC
- Rx
- OTC

...and Cost\(^{(2)}\)

- Marketing
  - Efficient marketing efforts through common brand strategy
- Administration
  - Moreover, administrative expenses could be lowered due to efficiency gains in the accounting efforts for both companies

€2.0-2.5mn total run rate synergies mainly driven by reduced marketing spend

Source: (1) EHS company information. (2) SAE company information.
Smooth Integration Process

- Both companies have presence in Venlo
  - EHS is headquartered in Venlo
  - SAE is headquartered in Venlo with additional offices in Germany, France, Belgium and Spain

- EHS targets Rx markets within the SAE’s current geographical coverage

- Existing service contracts between EHS and SAE across a number of functions (e.g.: Purchasing, IT, etc.)

Source: Company information.
Europa Apotheek at a Glance

1. Established and Trusted Player in an Attractive Market
   - c.80% of revenue from Rx products\(^{(1)}\)
   - c.25% Rx mailorder market share for 2017
   - Over 1mn parcels per year
   - Trusted partner since 2001

2. Highly Attractive Customer Profile
   - Focused on chronically ill patients with low churn rate
   - c.90% Repeat Orders / c.0.7% Returns
   - Total average cart size\(^{(2)}\) of c. €187
   - Cart size: c.€300 Rx\(^{(3)}\) vs. c.€60 OTC\(^{(4)}\)

3. Excellent Value Proposition
   - Smart \(\text{\textcircled{7}}\): 7 patient-care programs
   - Attractive RX bonus model

4. Experienced Management Team
   - Founder-led and long-term commitment
   - Long-Term Sector Experience

Source: Company information.
Note:  
\(\text{(1)}\) Based on 1H 2017. \(\text{(2)}\) Total gross revenue (incl. vat) / number of orders as per H1 2017. \(\text{(3)}\) Average cart size of orders containing Rx products. \(\text{(4)}\) Average cart size of pure OTC orders.
Market Leading Position in Germany

- **Market Share Rx #2**: 25% in 2017\(^{(1)}\)
- **Trusted Partner**: Top 5 online pharmacy for years\(^{(1)}\)
- **Top 5 German RX & OTC**: c. 80% RX and c. 20% OTC revenues
- **Mail Order Pioneer**: 16+ years experience

**Market Leading Position as Online Mail Order Pharmacy in Germany**

Source: Company information; (1) Sempora Study 2017.
Attractive Customer Profile, Growing Target Market

1. Attractive Cart Sizes
   - Average\(^{(1)}\) €187
   - €300 RX
   - €60 OTC

2. High Retention Rate
   - c.90% Repeat Orders
   - c.0.7% Returns

3. Customer Lifetime Value vs. Customer Acquisition Cost\(^{(2)}\)
   - CLV exceeds CAC within c. 3 months

Source: Company information.
Notes: (1) Cart size mixed: only orders that include Rx and OTC-Gross incl. VAT. (2) 100% TV spend allocated to new and existing customers based on revenue share.
Excellent Value Proposition

Patient Care Programmes for 7 Indications

- Asthma
- COPD
- Growth Hormone Deficiency
- Hepatitis C
- HIV
- Multiple Sclerosis
- Polypharmacy

Increased Medication Adherence: Win – Win – Win Situation\(^{(1,4)}\)

<table>
<thead>
<tr>
<th>Mean MPR in %</th>
<th>1st year</th>
<th>2nd year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>51.3</td>
<td>76.7</td>
</tr>
<tr>
<td>P = 0.003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smart Asthma/COPD participants</td>
<td>80.3</td>
<td>84.4</td>
</tr>
<tr>
<td>+30%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(\text{MPR} \geq 80\%\)

Therapy support by specialised experts

Value-add for:

1) Patients
   - Improved QoL\(^{(2,3)}\)

2) Health Care System
   - Cost savings due to lower rates of emergency room visits, hospital stays and absences from work\(^{(2)}\)

3) Europa Apotheek
   - Stronger customer loyalty of valuable patients (medication costs per patient per year (at 100% MPR) 15,000-30,000€ for MS and 460-2,200€ for Asthma/COPD)\(^{(4)}\)

Source: Company information.

Note: (1) a patient is non-adherent MPR < 80, a participant is adherent MPR ≥ 80% (2) Quality of Life ("QoL").

Successful Implementation of Bonus Model

- Increased attractiveness of online mail order for customers through competitive bonus model and attractive pricing which strengthens EAV’s B2C business

- Customers can use the bonus to reduce co-payment and/or to buy extra OTC / BPC products

- Augmented by offline to online shift and E-health trend

SAE + EHS Combined Seek to Create the Largest Online Pharmacy in Europe...

#1 Player in Continental European Pharma E-commerce(1)...
- We expect to become the #1 player in Continental Europe across Rx / OTC / BPC

Revenues Comparison – SAE+EHS vs. DocMorris

<table>
<thead>
<tr>
<th>Continent</th>
<th>H1 '17 Revenue €mn</th>
<th>1H 17</th>
<th>1H 17</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continental Europe(5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>H1 '17 Revenue €mn</td>
<td>79</td>
<td>178</td>
</tr>
</tbody>
</table>

Number of Continental European Countries Covered

<table>
<thead>
<tr>
<th>Country</th>
<th>Number of Countries Covered</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAE + EHS</td>
<td>7</td>
</tr>
<tr>
<td>DocMorris</td>
<td>1</td>
</tr>
</tbody>
</table>

Active Users As of H1 '17 in mn

<table>
<thead>
<tr>
<th>Country</th>
<th>Active Users</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAE</td>
<td>2.2</td>
</tr>
<tr>
<td>EHS</td>
<td>0.3</td>
</tr>
<tr>
<td>DocMorris</td>
<td>1.6</td>
</tr>
</tbody>
</table>

... With a Huge TAM(4)...
- Accessing the Rx market will expand our current TAM by c. 4X
- Benefit from the significant upside from limited Rx online penetration

OTC, Pharma BPC & Rx Market Size (2017) (excl. VAT)

<table>
<thead>
<tr>
<th>OTC &amp; Pharma BPC</th>
<th>Total Continental Europe: c. €164bn</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germany: €43bn</td>
<td>35bn</td>
</tr>
<tr>
<td>Germany: €132bn</td>
<td>27bn</td>
</tr>
<tr>
<td>Germany: €36bn</td>
<td>7bn</td>
</tr>
<tr>
<td>Germany: €105bn</td>
<td>36bn</td>
</tr>
<tr>
<td>Germany: €129bn</td>
<td>27bn</td>
</tr>
</tbody>
</table>

... With Fastest Growth(1)
- Combined entity will benefit from a fast growth trajectory

Revenue Growth in %

<table>
<thead>
<tr>
<th>Year</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY'15</td>
<td>15%</td>
</tr>
<tr>
<td>FY'16</td>
<td>10%</td>
</tr>
<tr>
<td>H1 16</td>
<td>36%</td>
</tr>
<tr>
<td>H1 17</td>
<td>17%</td>
</tr>
</tbody>
</table>

Source: (1) EHS company information and company filings as per Dutch GAAP, includes Rx and OTC. (2) Germany only. (3) Includes only Germany revenues, excludes Germany services. (4) Sempora, see page 10 for country split classification; figures rounded. (5) Excludes the UK and certain small EU countries; countries included are: Germany, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Portugal, Czech Republic, Hungary, Sweden, Bulgaria, Denmark, Slovakia, Norway, Austria. (6) As per IFRS.
...With an Attractive Combined Financial Profile

Pro Forma Revenues
(in €mn)

<table>
<thead>
<tr>
<th>Year</th>
<th>SAE</th>
<th>EHS</th>
<th>Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>177</td>
<td>141</td>
<td>318</td>
</tr>
<tr>
<td>H1 2017</td>
<td>127</td>
<td>80</td>
<td>207</td>
</tr>
</tbody>
</table>

Pro Forma Gross Profit & Margin
(in €mn)

<table>
<thead>
<tr>
<th>Year</th>
<th>SAE</th>
<th>EHS</th>
<th>Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>21</td>
<td>36</td>
<td>57</td>
</tr>
<tr>
<td>H1 2017</td>
<td>11</td>
<td>27</td>
<td>38</td>
</tr>
</tbody>
</table>

Source: Company information.
Note: Pro Forma financials are in line with IFRS accounting standard.
This is the Unique Opportunity to Create Europe’s Largest Online Pharmacy

- Serving the whole family
- Combining the OTC and Rx offering
- Creating leadership position in Europe
Regulatory Risks

• We are subject to a variety of regulations in the jurisdictions in which we operate, including but not limited to consumer protection laws, regulations governing e-commerce, data protection laws, online pharmacies and competition laws, and future regulations, as well as unexpected changes in the interpretation of existing regulations, which might impose additional requirements and other obligations on as well as limitations to our business.

• If a regulatory body alleges that we have engaged in the unauthorized practice of medicine or that our business proposition violates applicable country-specific laws, we may be subject to significant liabilities and may need to restrict our pharmaceutical offering in the future.

• Our plan to expand our business into new markets in Continental Europe will expose us to a variety of different local legal, regulatory, tax and cultural standards which we might fail to address or comply with.

• Adverse judgments or settlements resulting from legal proceedings could expose us to monetary damages and limit our ability to operate our business. In particular, there is a risk that mandatory manufacturer rebates which we pay to statutory sick funds will not be reimbursed to us by pharmaceutical companies.
### Legislative Risks for Rx Mail Order Sales in Germany

- **Cross-border mail-order sales of** prescription-only medicinal products (**Rx medications**) to German customers **is** – among others, for pharmacies located in the Netherlands – **allowed** under specific regulatory requirements in Germany.

- On 19 October 2016, the European Court of Justice (ECJ) decided that the German provisions regulating fixed **prices** for **Rx medications** are **not applicable to** (mail order) pharmacies from other EU countries (case C-148/15), whereas they are still applicable for German pharmacies.

- As a reaction to this decision, the German Federal Ministry of Health (BMG) provided a **draft on the prohibition of the sale by mail order of Rx medications** on 17 February 2017. After not having achieved a coalition’s majority, the proposal was not further pursued in the current legislative period of the German Federal Parliament.

- On 24 September 2017, the Federal Parliament in Germany was elected. Therefore no further parliamentary action was taken during the last legislative period. Due to the principle of discontinuity the draft of the former ministry is expired.

- **Alternative measures** have also been discussed at parliamentary level (but neither adopted), e.g. a **bonus cap** for Rx medications or a system of **maximum prices** for Rx medications.

- There is a **risk** that one of these legislative actions will be started again within the current or a future legislative period. In particular the implementation of a prohibition of mail-order sales of Rx medications would have a **massive material adverse effect on our business financial condition and results of operations**, as we could no longer mail order Rx medications to German customers. The implementation of one of the alternative measures could also adversely affect our business.
# Transaction Summary

## Transaction Summary
- Acquisition of EHS Europe Health Services B.V. (EHS), a leading online mail order pharmacy in Germany focusing on prescription drugs (operating including its 100% subsidiary Europa Apotheek Venlo B.V.)
- Creating Europe's largest online pharmacy with €318mn pro-forma 2016 sales through the combination of the Rx and OTC business
- Both companies with common roots, Shop Apotheke Europe N.V. (SAE) had been carved-out of EHS in 2015, prior to its IPO in October 2016

## Transaction Structure
- SAE to acquire 100% of the shares of EHS in an all-share transaction
- The transaction will be implemented by way of a contribution in kind of EHS shares against new SAE shares
- New SAE shares to be created via capital increase (subject to EGM approval)

## Valuation
- SAE will issue 2,724 (rounded) new SAE shares for each EHS share
- Total number of new SAE shares: 2,950,578
- The transaction values EHS at c.€126mn based on SAE’s 3-month volume weighted average price of €42.85 as of 22 September 2017¹)

## Lock-up
- New SAE shares received by EHS shareholders will be subject to a lock-up of 180 days

## Shareholders
- Core EHS shareholders²): Michael Köhler (in part through MK Beleggingsmaatschappij Venlo B.V.) (28.6%), Robert Hess (in part through Dr. Hess Verwaltungs-GmbH) (15.5%), Christoph Laubmann (9.9%) and Jan Pyttel (6.0%)
- Significant shareholder overlap due to the company’s combined group set-up prior to carve-out

## Path to Completion
- Approval at EGM on 06 November 2017
- Closing expected in November 2017
- New SAE shares to be listed on the Frankfurt Stock Exchange after AFM’s prospectus approval

---

¹) Based on FactSet and Xetra trading. ²) Shareholdings > 5%.
Proposal 1.

It is envisaged that in total 2,950,578 new ordinary shares in the share capital of the Company each having a nominal value of EUR 0.02 (the New Shares) will be issued to the shareholders of EHS Europe Health Services B.V. (Europa Apotheek). The New Shares will be issued under the following terms and conditions:

(a) the New Shares will be issued at par;
(b) the New Shares will be issued to the shareholders of Europa Apotheek in proportion to the aggregate amount of shares in the share capital of Europa Apotheek held by each of the shareholders of Europa Apotheek;
(c) the New Shares will be issued under the obligation to pay up the New Shares by way of contribution of all the shares in Europa Apotheek (the EA Shares).
Proposal 1. (continued)

The Transaction is considered to be a decision of the managing board of the Company (the Managing Board) that qualifies as an important change in the identity or character of the Company pursuant to the provisions of Section 2:107a paragraph 1 of the Dutch Civil Code, and is therefore subject to the approval of the general meeting; and more specifically subparagraph (c) of Section 2:107a paragraph 1, as the total consideration in connection with the Transaction amounts to at least one third of the value of the assets of the Company according to its consolidated balance sheet and explanatory notes set out in the Company's annual accounts for the financial year 2016.
3. Agenda item 3 (proposal 2): Issuance of new ordinary shares in the share capital of the Company in connection with the Transaction
Proposal 2.

As described in proposal 1, it is proposed to issue a total number of 2,950,578 New Shares under the following terms and conditions:

(a) the New Shares will be issued at par;
(b) the New Shares will be issued to the shareholders of Europa Apotheek in proportion to the aggregate amount of shares in the share capital of Europa Apotheek held by each of the shareholders of Europa Apotheek;
(c) the New Shares will be issued under the obligation to pay up the New Shares by way of contribution of all EA Shares.

In the Company’s annual general meeting held on 16 May 2017, the general meeting of the Company resolved to appoint the Managing Board for a period of five years as from the date of meeting (i.e. up to and including 15 May 2022) as the corporate body authorised to issue shares and grant rights to acquire shares, up to a maximum of 20% of the total number of issued shares of the Company outstanding on 1 January 2017 subject to the prior approval of the supervisory board of the Company (the Supervisory Board). On 1 January 2017 a total number of 9,069,878 issued shares of the Company were outstanding, and therefore the Managing Board is currently authorised to issue a maximum number of 1,813,975 (rounded down) New Shares.
Proposal 2. (continued)

On 25 September 2017, the Managing Board adopted written resolutions to approve the Transaction and to issue 1,813,975 New Shares in connection with the Transaction, which issue will become effective upon the execution of the relevant notarial deeds of transfer of EA Shares by the Dutch civil law notary (notaris) of Hogan Lovells International LLP.

It is proposed that the general meeting resolves to issue the remaining number of New Shares to be issued in connection with the Transaction, which is 1,136,603 New Shares. The issue of such 1,136,603 New Shares will also become effective upon the execution of the relevant notarial deeds of transfer of EA Shares, immediately after the issue of the 1,813,975 New Shares has come into effect.

The Supervisory Board approved the issue of the New Shares on 25 September 2017.
4. Agenda item 4.a. (proposal 3.a.): Designation of the Managing Board as the corporate body authorised to issue shares and/or grant rights to acquire shares subject to certain conditions
Proposal 3.a.

The current authorisation given pursuant to the resolution of the general meeting adopted in the Company’s annual general meeting held on 16 May 2017, will no longer be in force and effect as a result of the resolution of the Managing Board dated 25 September 2017 and the subsequent issuance of the 1,813,975 New Shares, which issuance will become effective upon the execution of the relevant notarial deeds of transfer of EA Shares by the Dutch civil law notary of Hogan Lovells International LLP.

It is proposed to appoint the Managing Board for a period of five years as from the date of this meeting (i.e. up to and including 5 November 2022), or until such date on which the general meeting revokes or again extends the authorisation, if earlier, as the corporate body authorised to issue shares and grant rights to acquire shares, subject to the prior approval of the Supervisory Board, up to a maximum of 20% of the total number of issued shares outstanding immediately after the New Shares have been issued.

It is proposed that this authorisation is granted to the Managing Board with the explicit reservation that the general meeting reserves its right to resolve on any issuance of shares and grant rights to acquire shares in the share capital of the Company at any time, including during the period that the Managing Board is also authorised to do so.
5. Agenda item 4.b. (proposal 3.b.): Designation of the Managing Board as the corporate body authorised to restrict or exclude the pre-emptive rights upon the issue of shares and/or the granting of rights to acquire shares as described in proposal 3.a. subject to certain conditions
Proposal 3.b.

The current authorisation given pursuant to the resolution of the general meeting taken in the Company’s annual general meeting held on 16 May 2017, will no longer be in force and effect as a result of the resolution of the Managing Board dated 25 September 2017 and the subsequent issuance of the 1,813,975 New Shares, which issuance will become effective upon the execution of the relevant notarial deeds of transfer of EA Shares by the Dutch civil law notary of Hogan Lovells International LLP.

It is proposed to appoint the Managing Board for a period of five years as from the date of this meeting (i.e. up to and including 5 November 2022), or until such date on which the general meeting revokes or again extends the authorisation, if earlier, as the corporate body authorised to restrict and exclude the pre-emptive rights accruing to shareholders in respect of the issue of shares or the granting of rights to acquire shares as described in proposal 3.a., subject to the prior approval of the Supervisory Board.

It is proposed that this authorisation is granted to the Managing Board with the explicit reservation that the general meeting reserves its right to resolve on any restriction and exclusion of pre-emptive rights accruing to shareholders in respect of the issue of such shares or the granting of rights to acquire such shares at any time, including during the period that the Managing Board is also authorised to do so.
6. Agenda item 5: Questions, answers and any other business
7. Collection of voting slips
8. Closing